Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

June 7, 2017

Study Completion Date

June 7, 2017

Conditions
HIV Infections
Interventions
DRUG

BMS-955176

HIV Maturation Inhibitor

DRUG

Atazanavir (ATV)

Atazanavir

DRUG

Ritonavir (RTV)

Ritonavir

DRUG

Dolutegravir (DTG)

Dolutegravir

DRUG

Tenofovir (TDF)

Tenofovir

Trial Locations (64)

1

GSK Investigational Site, Lima

100

GSK Investigational Site, Taipei

1141

GSK Investigational Site, Buenos Aires

1202

GSK Investigational Site, Buenos Aires

1632

GSK Investigational Site, Tembisa

2000

GSK Investigational Site, Rosario

2010

GSK Investigational Site, Darlinghurst

GSK Investigational Site, Darlinghurst, Sydney

GSK Investigational Site, Sydney

2092

GSK Investigational Site, Westdene

6001

GSK Investigational Site, Port Elizabeth

9301

GSK Investigational Site, Bloemfontein

10029

GSK Investigational Site, New York

10330

GSK Investigational Site, Bangkok

10467

GSK Investigational Site, The Bronx

14000

GSK Investigational Site, DF

30312

GSK Investigational Site, Atlanta

32330

GSK Investigational Site, Juárez

32720

GSK Investigational Site, DeLand

32804

GSK Investigational Site, Orlando

33308

GSK Investigational Site, Fort Lauderdale

33401

GSK Investigational Site, West Palm Beach

33614

GSK Investigational Site, Tampa

44280

GSK Investigational Site, Guadalajara

46202

GSK Investigational Site, Indianapolis

68000

GSK Investigational Site, Oaxaca City

74135

GSK Investigational Site, Tulsa

75246

GSK Investigational Site, Dallas

78705

GSK Investigational Site, Austin

81346

GSK Investigational Site, Kaohsiung City

90027

GSK Investigational Site, Los Angeles

90211

GSK Investigational Site, Beverly Hills

92262

GSK Investigational Site, Palm Springs

105275

GSK Investigational Site, Moscow

111311

GSK Investigational Site, Bogotá

190103

GSK Investigational Site, Saint Petersburg

350015

GSK Investigational Site, Krasnodar

620102

GSK Investigational Site, Yekaterinburg

664035

GSK Investigational Site, Irkutsk

7500922

GSK Investigational Site, Providencia, Santiago de Chile

8330074

GSK Investigational Site, Santiago

8360159

GSK Investigational Site, Santiago

06520

GSK Investigational Site, New Haven

C1405CKC

GSK Investigational Site, Ciudad Autónoma de Buenos Aires

X5000JJS

GSK Investigational Site, Córdoba

B7600FZN

GSK Investigational Site, Mar del Plata

V6Z 1Y6

GSK Investigational Site, Vancouver

V6Z 2C7

GSK Investigational Site, Vancouver

R3A 1R9

GSK Investigational Site, Winnipeg

M4N 3M5

GSK Investigational Site, Toronto

M5G 2N2

GSK Investigational Site, Toronto

H2L 4P9

GSK Investigational Site, Montreal

H2L 5B1

GSK Investigational Site, Montreal

H4A 3J1

GSK Investigational Site, Montreal

Unknown

GSK Investigational Site, Barranquilla

GSK Investigational Site, Bogotá

GSK Investigational Site, Santiago de Cali

03720

GSK Investigational Site, Distrito Federal

06700

GSK Investigational Site, Mexico City

CP 14080

GSK Investigational Site, Mexico City

Lima 11

GSK Investigational Site, Lima

Lima 14

GSK Investigational Site, Lima

Lima 31

GSK Investigational Site, Lima

00909-1711

GSK Investigational Site, San Juan

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY